The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
Open accessAbstract
Purpose: To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing schedules. Experimental Design: Patients with advanced solid malignancies and lymphomas were treated on three dose schedules: once every other week, twice weekly for 3 weeks every 28 days, and once weekly for 3 weeks every 28 days. First-cycle plasma pharmacokinetics and peripheral blood mononuclear cell histone acetylation were determined. Results: Twenty-seven patients received ≥149 courses of treatment. Hypophosphatemia and asthenia were dose limiting on the weekly and twice-weekly dosing schedules; there was no dose-limiting toxicity on the every other week schedule. Pharmacokinetic variables revealed dose-dependent and dose-proportional increases. Two of 27 patients showed partial remissions, including one patient with metastatic melanoma who had a partial response and has remained on study for >5 years. Six patients showed prolonged disease stabilization. Levels of histone H3 and H4 acetylation in peripheral blood mononuclear cells increased qualitatively but with a high degree of interpatient variation. Conclusions: MS-275 is well tolerated at doses up to 6 mg/m2 every other week or 4 mg/m2 weekly for 3 weeks followed by 1 week of rest and results in biologically relevant plasma concentrations and antitumor activity. Twice-weekly dosing was not tolerable due to asthenia, and further evaluation of this schedule was halted. The recommended dose for further disease-focused studies is 4 mg/m2 given weekly for 3 weeks every 28 days or 2 to 6 mg/m2 given once every other week.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most common toxicities observed included fatigue and hematologic, gastrointestinal, and metabolic AEs, similar to previous studies incorporating entinostat.11,14,15”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Zhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,639
Histone and chromatin cross-talk
Fischle, W., Wang, Y., & Allis, C. D. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00013-9 · Cited by 1,239
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 696
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 620
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 504
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
(2003) · PubMed · Cited by 465
Ryan, Q. C., Headlee, D. J., Acharya, M. R., Sparreboom, A., Trepel, J. B., Ye, Z., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 412
Research works printed but not linked: 2
- Wei Y, Qian, DZ, Ren M, et al. In vivo real-time imaging of transcriptional activation of the RARβ gene promoter by the histone deacetylase inhibitor MS-275 in a prostate cancer model. In: Proceedings of the AACR; 2004; Orlando, FL.
- Qian D, Wang XF, Ren MQ, et al. The histone deacetylase inhibitor MS-275 inhibits prostate tumor growth. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2003, Boston, MA.
Cited by
Sorted by citations
Items 101–175 of 175
Díaz-Núñez, M., Díez-Torre, A., Wever, O. D., Andrade, R., Arluzea, J., Silió, M., & Aréchaga, J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2693-3 · Cited by 23
Promises and challenges of anticancer drugs that target the epigenome
Verbrugge, I., Johnstone, R. W., & Bots, M. L. (2011) · Epigenomics · doi:10.2217/epi.11.82 · Cited by 22
Sharma, S., Ahmad, M., Bhat, J. A., Kumar, A., Kumar, M., Zargar, M. A., Hamid, A., & Shah, B. A. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.007 · Cited by 21
Sarker, P., Banik, A., Strömberg, R., Gudmundsson, G. H., Raqib, R., & Agerberth, B. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02570-16 · Cited by 21
Freundt, J. K., Frommeyer, G., Spieker, T., Wötzel, F., Grotthoff, J. S., Stypmann, J., Hempel, G., Schäfers, M. A., Jacobs, A. H., Eckardt, L., et al. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0294-x · Cited by 21
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
Sato, A. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s23874 · Cited by 21
Combating the Epigenome: Epigenetic Drugs Against Non-Hodgkin‘S Lymphoma
Hassler, M. R., Schiefer, A., & Egger, G. (2013) · Epigenomics · doi:10.2217/epi.13.39 · Cited by 24
Rösler, B., Wang, X., Keating, S. T., Joosten, L., Netea, M. G., & van de Veerdonk, F. L. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13192 · Cited by 20
Wang, B., Lyu, H., Pei, S., Song, D., Ni, J., & Liu, B. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1464849 · Cited by 18
Epigenetic Therapies in Melanoma—Targeting DNA Methylation and Histone Modification
Țigu, A. B., Ivancuta, A., Uhl, A., Sabo, A. C., Nistor, M., Mureșan, X. M., Cenariu, D., Timis, T., Diculescu, D. M., & Gulei, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051188 · Cited by 17
Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors
Gediya, P., Vyas, V. K., Carafa, V., Sitwala, N. D., Torre, L. D., Poziello, A., Kurohara, T., Suzuki, T., Sanna, V. K., Raguraman, V., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104801 · Cited by 16
Emerging drugs for cervical cancer
Dueñas‐González, A., Cetina, L., Coronel, J., & Cervantes-Madrid, D. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.683409 · Cited by 16
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells
Sung, J. J., Ververis, K., & Karagiannis, T. C. (2014) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2014.01.009 · Cited by 16
Dong, M., Ning, Z., Newman, M. J., Xu, J.-L., Dou, G., Cao, H., Shi, Y., Gingras, M. A., Lu, X., & Feng, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3529 · Cited by 15
Lu, H., Chen, Y., Yang, B., & You, Q. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.002 · Cited by 14
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer
Cho, J. H., Öezkan, F., Koenig, M. J., Otterson, G. A., Herman, J. G., & He, K. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0110-5 · Cited by 14
Venza, M., Visalli, M., Oteri, R., Agliano, F., Morabito, S., Teti, D. V., & Venza, I. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.024 · Cited by 13
Gupta, N., Sitwala, N. D., & Patel, K. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1057-2 · Cited by 13
Clinical Applications of Histone Deacetylase Inhibitors
Park, J., Terranova-Barberio, M., Zhong, A. Y., Thomas, S., & Münster, P. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805388-1.00040-7 · Cited by 12
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents
Makgoba, T. B., Kapp, E., Egieyeh, S. A., & Joubert, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2363890 · Cited by 12
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Sethy, B., Upadhyay, R., Narwanti, I., Yu, Z.-Y., Lee, S., & Liou, J. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02023-7 · Cited by 11
The power and the promise of epigenetic drugs in oncology
Scandolara, T. B., Siqueira, I. V. M., Pinto, L. F. R., & Soares‐Lima, S. C. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1622115 · Cited by 10
The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method.
Wu, Q. F., Zhang, Q., Wen, C., Hu, L., Wang, X., & Lin, G. (2015) · PubMed Central · Cited by 9
Kim, S. J., Kim, U. J., Yoo, H. Y., Choi, Y. J., & Kang, K. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124377 · Cited by 9
Terracciano, S., Chini, M. G., Riccio, R., Bruno, I., & Bifulco, G. (2012) · ChemMedChem · doi:10.1002/cmdc.201100531 · Cited by 9
Ning, Z. (2020) · Translational Breast Cancer Research · doi:10.21037/tbcr.2020.03.06 · Cited by 8
Zhong, G.-P., Chen, J.-Y., Bi, H., Qin, X., Dai, C.-L., Liu, J., Chen, X., Zeng, G., Huang, Z., & Huang, M. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.09.023 · Cited by 8
Histone Deacetylase Inhibitors in Medical Therapeutics
Chun, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00034-x · Cited by 8
Chromatin dynamics at the core of kidney fibrosis
Tampe, B., & Zeisberg, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.015 · Cited by 7
Villoria-González, A., Zierfuss, B., Parzer, P., Heuboeck, E., Zujovic, V., Waidhofer‐Söllner, P., Ponleitner, M., Rommer, P. S., Göpfert, J. C., Forss‐Petter, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121696 · Cited by 6
Epigenetic Therapy in Lung Cancer and Mesothelioma
Baird, A., Richard, D. J., O'Byrne, K. J., & Gray, S. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00009-4 · Cited by 6
Shulman, D. S., Vo, K. T., Balis, F. M., Lindsay, H., Bagatell, R., Place, A. E., Chi, S. N., Shusterman, S., Ezrre, S., Czaplinski, J. T., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71417 · Cited by 5
Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 5
Melanoma and Epigenetic Treatment: Past and Future
Porta, C. A. M. L. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228760 · Cited by 5
Mohamed, E. A., Meshali, M. M., & Sayre, C. L. (2012) · Journal of Chromatography & Separation Techniques · doi:10.4172/2157-7064.1000118 · Cited by 5
Ma, Y. T., Leonard, S. M., Gordon, N. S., Anderton, J. A., James, C. D., Huen, D. S., Woodman, C. B. J., & Palmer, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.18879 · Cited by 5
Dunaway, L. S., Cook, A. K., Kellum, C. E., Edell, C., Botta, D., Molina, P. A., Sedaka, R. S., d’Uscio, L. V., Katušić, Z. S., Pollock, D. M., et al. (2024) · Acta Physiologica · doi:10.1111/apha.14201 · Cited by 3
Omran, M. M., Vafaei, S., Alkhrait, S., Yang, Q., & Al-Hendy, A. A. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70626 · Cited by 5
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Kim, J.-A., Crawford, K. A., Spada, P. A., Martin, L. R., Zhang, J., Wong, R., Reid, J. M., Stewart, C. F., Frank, T. M., Liu, Q., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40751-z · Cited by 4
Recent Studies on HDAC Inhibitors Acting against Prostate Cancer
Shaik, B., Zafar, T., & Gupta, S. P. (2020) · Current Enzyme Inhibition · doi:10.2174/1573408016666200402092557 · Cited by 4
De-mystifying the Epigenetic Free for All: Pharmacophore Modeling for Epigenetic Cancer Therapy
de Almeida, V. R., Brunetto, A. L., Schwartsmann, G., Roesler, R., & Abujamra, A. L. (2011) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.1000102e · Cited by 4
MS-275 Chemical Analogues Promote Hemoglobin Production and Erythroid Differentiation of K562 Cells
Voskou, S., Phylactides, M., Afantitis, A., Melagraki, G., Tsoumanis, A., Koutentis, P. A., Mitsidi, T., Mirallai, S. I., & Kleanthous, M. (2019) · Hemoglobin · doi:10.1080/03630269.2019.1626740 · Cited by 4
Marsh, A. M., Narramore, R., Chapple, K. S., Lobo, A., Wild, J. R. L., & Corfe, B. M. (2013) · Clinical Investigation · doi:10.4155/cli.13.36 · Cited by 3
Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer
Purohit, T. A., Bahr, K., Yang, B., Schultz, Z. D., Lewis, P. W., Denu, J. M., & Jarrard, D. F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1730397 · Cited by 2
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors
Schäker‐Hübner, L., & Hansen, F. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00619 · Cited by 3
Cheng, S., Kolendowski, B., Ramos-Valdes, Y., Shepherd, T. G., & DiMattia, G. E. (2026) · Cells · doi:10.3390/cells15080673 · Cited by 2
Ota, Y., Itoh, Y., Takada, Y., Yamashita, Y., Hu, C., Horinaka, M., Sowa, Y., Masuda, M., Sakai, T., & Suzuki, T. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117632 · Cited by 2
Histone deacetylase inhibitors in medical therapeutics
Chun, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00029-3 · Cited by 2
Clinical Applications of Histone Deacetylase Inhibitors
Pacaud, R., García, J., Thomas, S., & Münster, P. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00002-5 · Cited by 2
Cai, W., Pei, X., Ye, X., Zhai, Y., Wu, N., Wang, Z., & Lu, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117718 · Cited by 1
Zhao, R., Zhang, B., Han, M., Lv, M., Sun, J., & Zhou, X. (2026) · Pharmaceuticals · doi:10.3390/ph19050689 · Cited by 1
Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects
Tedjaseputra, A., Galli, S., Ibrahim, M., Harrison, C. N., & McLornan, D. P. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1149467 · Cited by 1
Rao‐Bindal, K. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Clinical Trials and Translational Applications in Cancer Therapy
Khabele, D., & Beech, D. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_21
Polireddy, K. (2015) · KU ScholarWorks (The University of Kansas)
Sumpf, K. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6571
Investigation of Novel Antimalarial Agents and Novel Target Identification Approaches
Sumanadasa, S. D. M. (2015) · Griffith Research Online · doi:10.25904/1912/756
Ito, A., & Yoshida, M. (2017) · Springer eBooks · doi:10.1007/978-4-431-56529-1_3
Epigenomic Imaging of Neuropsychiatric Diseases
Bahari‐Javan, S. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4280
Recent Advance of Histone Modification in Gastric Cancer : A Review
Shekh, A. S., Mangate, K. S., Khedekar, N. D., Ayaz, M. A. M., & Biyani, K. R. (2022) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-7018
Floris, G., Dêbiec‐Rychter, M., Sciot, R., Stefan, C., Fieuws, S., Machiels, K., Atadja, P. W., Woźniak, A., Faa, G., & Schöffski, P. (2023) · doi:10.1158/1078-0432.c.6517830.v1
Epigenetic therapy in lung cancer
Conroy, M. R., O’Connor, Á., Bailey‐Whyte, M., & Dowling, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00004-0
Alshawli, A. S., Ahmed, T. A., Ahmed, F., Haque, A., El‐Say, K. M., Omar, A. M., & Abu-Elmagd, M. M. (2024) · Journal of Nanotechnology · doi:10.1155/2024/8207090
Safety Considerations of Targeting Epigenetic Mechanisms
Lovatt, C. A., Liu, S., & Scott, C. W. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00158
Emerging Technologies for Epigenetic Drug Discovery
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part2
Cancer Stem Cells in Gastrointestinal Cancers
Li, M., Li, J., He, D., & Liu, M. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_12
Masuda, N., Tamura, K., Yasojima, H., Shimomura, A., Sawaki, M., Lee, M.-J., Yuno, A., Trepel, J., Kimura, R., Nishimura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17079331
Masuda, N., Tamura, K., Yasojima, H., Shimomura, A., Sawaki, M., Lee, M.-J., Yuno, A., Trepel, J., Kimura, R., Nishimura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17079337
Masuda, N., Tamura, K., Yasojima, H., Shimomura, A., Sawaki, M., Lee, M.-J., Yuno, A., Trepel, J., Kimura, R., Nishimura, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17079334
Epigenetics in angiogenesis, gastrointestinal cancer progression and its clinical significance
Chandana, A. N., & Bhagya, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00012-6
Metadata
- Authors
- Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G.
- Affiliations
- University of Colorado Cancer Center (US)
- Vanderbilt-Ingram Cancer Center (US)
- 1University of Colorado Cancer Center, Aurora, Colorado;
- 3Bayer Healthcare, Seattle, Washington; and
- Bayer (Germany) (DE)
- Venue
- Clinical Cancer Research
- Published
- 2008-07-15
- Volume
- 14
- Issue
- 14
- Pages
- 4517-4525
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC2813676
- OpenAlex
- W2170925020
- Cited by
- 171
- References
- 21
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 9 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 13
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (NIH K12)
- Cancer Center, University of Colorado
- National Cancer Institute (CA-86913, K24CA106349, K12CA086913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- entinostat, histone deacetylase inhibitors, oral administration, dosing regimen, pharmacokinetics, refractory solid tumors, lymphoma, hypophosphatemia, asthenia, histone H3 and H4 acetylation, peripheral blood mononuclear cells, metastatic melanoma, anticancer activity, toxicity
- MeSH terms
- Administration, Oral, Adult, Aged, Antineoplastic Agents, Benzamides, Enzyme Inhibitors, Female, Humans, Lymphoma, Male, Middle Aged, Neoplasms, Pyridines, Area Under Curve, Maximum Tolerated Dose, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
